$ cat ./records/gates-foundation-invests-40-million-to-scale-mrna-vaccine-manufac-2023.txt
Gates Foundation Invests $40 Million to Scale mRNA Vaccine Manufacturing in Africa
[RECORD.TXT] · cat --full
The Gates Foundation announced $40 million to advance mRNA vaccine manufacturing across low- and middle-income countries, with $5 million each to Institut Pasteur de Dakar in Senegal and Biovac in South Africa, $20 million to Quantoom Biosciences to cut mRNA production costs by 50 percent, and the remainder to other regional manufacturers. The initiative aims to end Africa's reliance on imported vaccines by building domestic mRNA production capacity on the continent.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation and Wellcome Fund M72 Tuberculosis Vaccine Phase III Trial with $550 Million
Next →
Gates Foundation awarded IOM a grant for health programs serving mobile and displaced populations in southern Afghanistan
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.